Preclinical & Clinical Pharmacology & Therapeutics for Adenocarcinomas Arising i

需要创新的策略来改善胃肠道腺癌患者的预后。我们正在研究调节剂和细胞毒性剂与氟尿嘧啶在体外的相互作用，以确定潜在临床应用的最佳序列。研究旨在阐明具有抗结肠癌细胞系活性的新型药物的最佳给药方案和作用机制，以促进其合理的临床使用。我们实施临床试验，包括临床药代动力学，生化和/或分子终点。发展了新的分析测定方法来测定抗癌药物的药代动力学和细胞内药效学。我们的目标是为GI癌症患者开发新的药物和药物组合，并开发选择性靶向基因组不稳定性和/或受损的程序性细胞死亡途径的癌细胞的策略。

Innovative strategies are needed to improve the prognosis of patients with adenocarcinomas arising in the gastrointestinal tract. We are studying the interaction of modulatory & cytotoxic agents with fluorouracil in vitro to define optimal sequences for potential clinical use. Studies are designed to elucidate the optimal schedule of administration & mechanism of action of novel agents with activity against colon cancer cell lines to facilitate their rational clinical use. We implement clinical trials that incorporate clinical pharmacokinetic, biochemical &/or molecular endpoints. New analytic assay methods are developed to measure the pharmacokinetics & intracellular pharmacodynamics of the anticancer agents. Our goal is to develop new agents & drug combinations for patients with GI cancers, & to develop strategies that selectively target cancer cells with genomic instability &/or impaired programmed cell death pathways.